Skip to main content
Clinical Trials/NCT05572788
NCT05572788
Recruiting
Not Applicable

Randomized Trial of Rectal Indomethacin to Prevent Acute Pancreatitis in Patients Undergoing Endoscopic Ultrasound-guided Fine Needle Aspiration of Pancreatic Cysts

Orlando Health, Inc.1 site in 1 country600 target enrollmentSeptember 26, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreatic Cyst
Sponsor
Orlando Health, Inc.
Enrollment
600
Locations
1
Primary Endpoint
Rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The aim of this randomized trial is to compare the rate of post-procedure pancreatitis in patients undergoing EUS-FNA of pancreatic cysts; patients will receive either a single dose of indomethacin or placebo administered rectally, during EUS-FNA.

Detailed Description

Pancreatic cysts are pre-malignant lesions and are being increasingly diagnosed on cross-sectional imaging. Endoscopic ultrasound (EUS) is performed to further evaluate pancreatic cysts, and fine needle aspiration (FNA) is conducted to obtain a sample of the cystic fluid for analysis and examination for malignant cells. Acute pancreatitis is a complication of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of pancreatic cysts, which can lead to significant morbidity and substantial health care costs. The aim of this randomized trial is to compare the rate of post-procedure pancreatitis in patients undergoing EUS-FNA of pancreatic cysts; patients will receive either a single dose of indomethacin or placebo administered rectally, during EUS-FNA.

Registry
clinicaltrials.gov
Start Date
September 26, 2022
End Date
December 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years
  • Suspected or confirmed pancreatic cyst seen on imaging, requiring EUS-FNA

Exclusion Criteria

  • Unable to obtain consent from the participant or the participant's legally authorized representative (LAR)
  • Intrauterine pregnancy
  • Hypersensitivity reaction to Aspirin or NSAIDs
  • Patients with known history of chronic pancreatitis
  • Patients with known renal failure

Outcomes

Primary Outcomes

Rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts

Time Frame: 30 days

Post-procedure pancreatitis is defined as the development of new or increased abdominal pain consistent with acute pancreatitis, and elevated amylase or lipase at least three times the upper limit of normal .

Secondary Outcomes

  • Rate of procedure-related adverse events(30 days)
  • Disease-related adverse events(30 days)
  • Rate of mild, moderate and severe pancreatitis post-FNA(30 days)
  • Length of hospitalization in any patient hospitalized with any adverse event(30 days)
  • Length of hospitalization in any patient hospitalized with acute pancreatitis(30 days)

Study Sites (1)

Loading locations...

Similar Trials